Omniose is developing a bioconjugate platform to create vaccines against multidrug resistant superbugs.

AstraZeneca has acquired vaccine bioconjugation specialist Omn | AstraZeneca has acquired vaccine bioconjugation specialist ...

A 2025 review in Discover Immunity explores how bacterial extracellular vesicles can serve as self-adjuvanted vaccine platforms, highlighting their immunomodulatory potential and the challenges in ...

Columbia researchers have engineered probiotic bacteria that educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines that take advantage of bacteria's ...

AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious ​bacterial infections ...

One in two women will experience a UTI in their lifetime – with one in four developing a chronic infection. Australian ...

Presentations will feature Gamma-PN clinical progress and early Gamma-SU findings supporting a broader approach to human and animal health GPN's lead vaccine candidate, Gamma-PN, is a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Israeli researchers have developed a new vaccine that is “100% effective” against bacteria that is deadly to humans. The announcement came from Tel Aviv University, which teamed up with the Israel ...